Zacks Investment Research
02 Jul 2026, 15:46 UTC · 3h ago
Vertex Gets FDA Nod for Expanded Use of Casgevy in SCD & TDT
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
02 Jul 2026, 15:46 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
The FDA has approved Vertex Pharmaceuticals' gene therapy, Casgevy, for children as young as two years old with sickle cell disease or transfusion-dependent beta thalassemia. — Expanding the treatable patient population to include young children significantly increases the long-term addressable market for the drug.
+0.60Vertex believes Casgevy has multibillion-dollar commercial potential if the ramp-up is successful over the next few years. — High revenue projections for a core product drive long-term valuation and investor optimism.
+0.40Vertex shares profits from the Casgevy program with CRISPR Therapeutics in a 60:40 ratio. — This establishes the financial benefit distribution between the two partners, affecting the net impact on Vertex's bottom line.
+0.20Continue reading
6 related stories
Top 2 movers · tap to explore
Casgevy sales were $42.9 million in Q1 2026, a decrease from $54.3 million in Q4 2025. — A sequential decline in revenue is typically a negative signal, though the company attributes this to infusion variability.
-0.20Which stocks this story touches
Received FDA approval to expand the use of Casgevy to children as young as two years old.
Benefits from the FDA approval of Casgevy through a profit-sharing agreement with Vertex.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
3h ago
